Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy.
Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):699-705. doi: 10.1016/j.numecd.2010.03.006. Epub 2010 Nov 5.
We evaluated the relationship between insulin resistance (IR) and insulin secretion with the metabolic syndrome (MS) in 885 subjects (377 men/508 women, age 49±11 years, BMI 29±5.2kgm(-2)) at risk of diabetes enrolled in the genetics, pathophysiology and evolution of type 2 diabetes (GENFIEV) study.
All subjects underwent a 75-g oral glucose tolerance test (OGTT) for the estimation of plasma levels of glucose and C-peptide, as well as fasting insulin and lipid profile. IR was arbitrarily defined as HOMA-IR value above the 75th centile of normal glucose tolerance (NGT) subjects. Overall MS prevalence (National Cholesterol Treatment Panel-Adult Treatment Panel (NCEP-ATPIII) criteria) was 33%, 19% in subjects with NGT, 42% in impaired fasting glucose (IFG), 34% in impaired glucose tolerance (IGT), 74% in IFG+IGT subjects, and 56% in newly diagnosed diabetic patients. Prevalence was slightly higher with IDF criteria. MS prevalence was >50% in subjects with 2h glucose >7.8mmoll(-1), independently of fasting plasma glucose. IR prevalence was higher in subjects with MS than in those without (63% vs. 23%; p<0.0001) and increased from 54% to 73% and 88% in the presence of three, four or five traits, respectively. IR occurred in 42% of subjects with non-diabetic alterations of glucose homeostasis, being the highest in those with IFG+IGT (IFG+IGT 53%, IFG 45%, IGT 38%; p<0.0001). Individuals with MS were more IR irrespective of glucose tolerance (p<0.0001) with no difference in insulinogenic index. Hypertriglyceridaemia (OR: 3.38; Confidence Interval, CI: 2.294.99), abdominal obesity (3.26; CI: 2.18-4.89), hyperglycaemia (3.02; CI: 1.80-5.07) and hypertension (1.69; CI: 1.12-2.55) were all associated with IR.
These results show that in subjects with altered glucose tolerance (in particular IFG+IGT) MS prevalence is high and is generally associated to IR. Some combinations of traits of MS may significantly contribute to identify subjects with IR.
我们评估了 885 名有糖尿病风险的受试者(377 名男性/508 名女性,年龄 49±11 岁,BMI 29±5.2kg/m²)中胰岛素抵抗(IR)与代谢综合征(MS)之间的关系,这些受试者参与了基因、病理生理学和 2 型糖尿病的演变(GENFIEV)研究。
所有受试者均接受 75g 口服葡萄糖耐量试验(OGTT),以评估血浆葡萄糖和 C 肽水平以及空腹胰岛素和血脂谱。IR 被任意定义为高于正常葡萄糖耐量(NGT)受试者第 75 百分位数的 HOMA-IR 值。总体 MS 患病率(国家胆固醇教育计划-成人治疗专家组(NCEP-ATPIII)标准)为 33%,NGT 受试者为 19%,空腹血糖受损(IFG)为 42%,糖耐量受损(IGT)为 34%,IFG+IGT 受试者为 74%,新诊断为糖尿病患者为 56%。用 IDF 标准,患病率略高。无论空腹血糖如何,2h 血糖>7.8mmol/L 的受试者中 MS 的患病率>50%。MS 受试者的 IR 患病率高于无 MS 受试者(63% vs. 23%;p<0.0001),且随着三个、四个或五个特征的存在,IR 患病率分别从 54%增加至 73%和 88%。在非糖尿病葡萄糖稳态改变的受试者中,IR 发生率为 42%,IFG+IGT 患者最高(IFG+IGT 53%、IFG 45%、IGT 38%;p<0.0001)。无论葡萄糖耐量如何,患有 MS 的个体的 IR 发生率更高(p<0.0001),而胰岛素生成指数没有差异。高甘油三酯血症(OR:3.38;置信区间,CI:2.29-4.99)、腹型肥胖(3.26;CI:2.18-4.89)、高血糖(3.02;CI:1.80-5.07)和高血压(1.69;CI:1.12-2.55)均与 IR 相关。
这些结果表明,在葡萄糖耐量改变的受试者中(特别是 IFG+IGT),MS 的患病率较高,通常与 IR 相关。MS 的某些特征组合可能显著有助于识别 IR 患者。